AIM ImmunoTech

AIM ImmunoTech
AIM
AMEX: AIM
IndustryBiopharmaceutical
Headquarters
Ocala, Florida
,
USA
Key people
CEO Thomas K. Equels, J.D.
COO Peter W. Rodino III, J.D.
CFO Ellen Lintal
ProductsAmpligen
Alferon
ServicesCancer and immunotherapy research
Total assets$ 64.584 million Increase (2020[1])

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders.[2] Founded in 1990, the company has twenty-three employees.[3]

The company has created an immunomodulatory double stranded RNA drug called Ampligen.[4]

It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome.[5]

  1. ^ "Date: 3/31/2021 Form: 10-K - Annual Report, for AIM IMMUNOTECH INC".
  2. ^ Greenberg, Herb (1998-09-18). "Battle Royale Brewing: Hemispherx Biopharma and Asensio Tangle". TheStreet.com. Archived from the original on 6 June 2011. Retrieved 24 August 2009.
  3. ^ "Hemispherx Biopharma, Inc". BusinessWeek. Archived from the original on 22 September 2012. Retrieved 24 August 2009.
  4. ^ "Hemispherx licensed for chemical compound". Philadelphia Business Journal. 2006-08-29. Archived from the original on 25 October 2012. Retrieved 24 August 2009.
  5. ^ "Hemispherx Biopharma Inc. (use of Ampligen for chronic fatigue syndrome)". Philadelphia Business Journal. 2000-10-06. Retrieved 24 August 2009.